Cerity Partners LLC Increases Holdings in Sanofi (NASDAQ:SNY)

Cerity Partners LLC lifted its holdings in Sanofi (NASDAQ:SNY) by 37.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 127,083 shares of the company’s stock after acquiring an additional 34,785 shares during the period. Cerity Partners LLC’s holdings in Sanofi were worth $7,324,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in SNY. Meridian Wealth Management LLC increased its holdings in Sanofi by 13.3% in the 3rd quarter. Meridian Wealth Management LLC now owns 42,369 shares of the company’s stock valued at $2,442,000 after acquiring an additional 4,972 shares during the last quarter. Icon Wealth Advisors LLC grew its position in shares of Sanofi by 7,954.4% during the third quarter. Icon Wealth Advisors LLC now owns 292,779 shares of the company’s stock valued at $16,873,000 after purchasing an additional 289,144 shares in the last quarter. Citigroup Inc. lifted its position in shares of Sanofi by 2.5% in the third quarter. Citigroup Inc. now owns 631,672 shares of the company’s stock worth $36,403,000 after buying an additional 15,348 shares in the last quarter. Raymond James Trust N.A. lifted its position in shares of Sanofi by 4.0% in the third quarter. Raymond James Trust N.A. now owns 55,200 shares of the company’s stock worth $3,181,000 after buying an additional 2,120 shares in the last quarter. Finally, Eagle Asset Management Inc. grew its holdings in Sanofi by 11.1% during the 3rd quarter. Eagle Asset Management Inc. now owns 6,582 shares of the company’s stock valued at $379,000 after buying an additional 658 shares in the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Trading Up 0.9 %

Shares of NASDAQ SNY opened at $48.72 on Thursday. The business’s 50 day moving average price is $53.17 and its 200-day moving average price is $52.15. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The company has a market cap of $123.64 billion, a price-to-earnings ratio of 24.86, a PEG ratio of 1.22 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business’s revenue was up 12.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.55 earnings per share. On average, sell-side analysts expect that Sanofi will post 4.29 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.